Literature DB >> 32121619

RHΔgra17Δnpt1 Strain of Toxoplasma gondii Elicits Protective Immunity Against Acute, Chronic and Congenital Toxoplasmosis in Mice.

Qin-Li Liang1, Li-Xiu Sun1, Hany M Elsheikha2, Xue-Zhen Cao1, Lan-Bi Nie1, Ting-Ting Li1, Tao-Shan Li1, Xing-Quan Zhu1,3, Jin-Lei Wang1.   

Abstract

: In the present study, a dense granule protein 17 (gra17) and novel putative transporter (npt1) double deletion mutant of Toxoplasma gondii RH strain was engineered. The protective efficacy of vaccination using RHΔgra17Δnpt1 tachyzoites against acute, chronic, and congenital toxoplasmosis was studied in a mouse model. Immunization using RHΔgra17Δnpt1 induced a strong humoral and cellular response, as indicated by the increased levels of anti-T. gondii specific IgG, interleukin 2 (IL-2), IL-10, IL-12, and interferon-gamma (IFN-γ). Vaccinated mice were protected against a lethal challenge dose (103 tachyzoites) of wild-type homologous (RH) strain and heterologous (PYS and TgC7) strains, as well as against 100 tissue cysts or oocysts of Pru strain. Vaccination also conferred protection against chronic infection with 10 tissue cysts or oocysts of Pru strain, where the numbers of brain cysts in the vaccinated mice were significantly reduced compared to those detected in the control (unvaccinated + infected) mice. In addition, vaccination protected against congenital infection with 10 T. gondii Pru oocysts (administered orally on day 5 of gestation) as shown by the increased litter size, survival rate and the bodyweight of pups born to vaccinated dams compared to those born to unvaccinated + infected dams. The brain cyst burden of vaccinated dams was significantly lower than that of unvaccinated dams infected with oocysts. Our data show that T. gondii RHΔgra17Δnpt1 mutant strain can protect mice against acute, chronic, and congenital toxoplasmosis by balancing inflammatory response with immunogenicity.

Entities:  

Keywords:  Toxoplasma gondii; dense granule protein 17; immunization; live-attenuated vaccine; novel putative transporter 1

Year:  2020        PMID: 32121619     DOI: 10.3390/microorganisms8030352

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  6 in total

Review 1.  Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.

Authors:  Hany M Elsheikha; Christina M Marra; Xing-Quan Zhu
Journal:  Clin Microbiol Rev       Date:  2020-11-25       Impact factor: 26.132

2.  Deletion of Toxoplasma Rhoptry Protein 38 (PruΔrop38) as a Vaccine Candidate for Toxoplasmosis in a Murine Model.

Authors:  Yayun Wu; Zihui Zhou; Zhu Ying; Ying Xu; Jing Liu; Qun Liu
Journal:  Biomedicines       Date:  2022-06-06

Review 3.  Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development.

Authors:  Ki-Back Chu; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2021-04-21

Review 4.  Vaccines in Congenital Toxoplasmosis: Advances and Perspectives.

Authors:  Mariana Barros; Daniela Teixeira; Manuel Vilanova; Alexandra Correia; Natercia Teixeira; Margarida Borges
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

Review 5.  Key Limitations and New Insights Into the Toxoplasma gondii Parasite Stage Switching for Future Vaccine Development in Human, Livestock, and Cats.

Authors:  Marie-Noëlle Mévélec; Zineb Lakhrif; Isabelle Dimier-Poisson
Journal:  Front Cell Infect Microbiol       Date:  2020-11-25       Impact factor: 5.293

6.  Comparative Phosphoproteomic Analysis of Sporulated Oocysts and Tachyzoites of Toxoplasma gondii Reveals Stage-Specific Patterns.

Authors:  Ze-Xiang Wang; Liang Che; Rui-Si Hu; Xiao-Lin Sun
Journal:  Molecules       Date:  2022-02-02       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.